Compare First Citizens BancShares Inc (FCNCA) vs Summit Therapeutics Inc (SMMT) Price & Performance

First Citizens BancShares (FCNCA) trades at $2,133.72, up 3.47% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with a trailing P/E of 11.94 and consistent earnings beats, including a Q1 2026 EPS of $44.86 versus $39.56 expected. Recent strategic moves include plans to retire the Silicon Valley Bank brand and expand commercial banking capabilities in Q4 2026.

The outlook is supported by solid profitability with a 24.35% net income margin and a shareholder-friendly dividend. Key risks include margin pressure and credit risk exposure from the legacy SVB portfolio. Analyst consensus is cautious with an 81.82% hold rating, though the consensus price target of $2,320 suggests modest upside from current levels.

Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.

SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.